Literature DB >> 12154010

Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus.

Ritsuko Katoh-Semba1, Tomiko Asano, Hiroshi Ueda, Rika Morishita, Ikuo K Takeuchi, Yutaka Inaguma, Kanefusa Kato.   

Abstract

The dentate gyrus of the hippocampus, generating new cells throughout life, is essential for normal recognition memory performance. Reduction of brain-derived neurotrophic factor (BDNF) in this structure impairs its functions. To elucidate the association between BDNF levels and hippocampal neurogenesis, we first conducted a search for compounds that stimulate endogenous BDNF production in hippocampal granule neurons. Among ion channel modulators tested, riluzole, a neuroprotective agent with anticonvulsant properties that is approved for treatment of amyotrophic lateral sclerosis, was highly effective as a single dose by an intraperitoneal injection, causing a rise in BDNF localized in dentate granule neurons, the hilus, and the stratum radiatum of the CA3 region. Repeated, but not single, injections resulted in prolonged elevation of hippocampal BDNF and were associated with increased numbers of newly generated cells in the granule cell layer. This appeared due to promoted proliferation rather than survival of precursor cells, many of which differentiated into neurons. Intraventricular administration of BDNF-specific antibodies blocked such riluzole effects, suggesting that BDNF increase is necessary for the promotion of precursor proliferation. Our results suggest the basis for a new strategy for treatment of memory dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154010     DOI: 10.1096/fj.02-0143fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  64 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 2.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

3.  Neuroprotective effects of riluzole in Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciammola; Claudio Colonnese; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-06       Impact factor: 9.236

Review 4.  The Dynamics of Neurosteroids and Sex-Related Hormones in the Pathogenesis of Alzheimer's Disease.

Authors:  Milad Hasanpour; Alireza Nourazarian; Mohammad Hossein Geranmayeh; Masoud Nikanfar; Fatemeh Khaki-Khatibi; Reza Rahbarghazi
Journal:  Neuromolecular Med       Date:  2018-05-04       Impact factor: 3.843

Review 5.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

Review 6.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Authors:  Ferdinando Squitieri; Sara Orobello; Milena Cannella; Tiziana Martino; Pantaleo Romanelli; Giampiero Giovacchini; Luigi Frati; Luigi Mansi; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

8.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Authors:  Sanjay J Mathew; James W Murrough; Marije aan het Rot; Katherine A Collins; David L Reich; Dennis S Charney
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-17       Impact factor: 5.176

Review 9.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 10.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.